Safety, Tolerability, Pharmacokinetics, and Efficacy of LY3053102 With 12 Weeks of Treatment in Patients With Type 2 Diabetes Mellitus
Latest Information Update: 07 Nov 2021
At a glance
- Drugs LY 3053102 (Primary) ; Exenatide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 24 Feb 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 09 Feb 2015 Planned End Date changed from 1 Feb 2016 to 1 Feb 2015 as reported by ClinicalTrials.gov record
- 02 Feb 2015 Planned End Date changed from 1 Jan 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov record.